Accelerating Drug Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Accelerating Drug Development
FDA's new safety program, Critical Path Initiative, and user-fee proposal seek to reinvigorate pharmaceutical R&D.


Pharmaceutical Technology


Testing and analysis. FDA also supports efforts to understand more fully how nanotechnology may contribute to the development of new treatments. FDA is collaborating with NIST and the National Cancer Institute Nanotechnology Characterization Laboratory to develop characterization assays and methods for preclinical and early clinical testing of such products as a way to better understand their promise for providing more effective and less toxic cancer therapies. FDA has established a Nanotechnology Task Force and Nanotechnology Interest Group of review scientists with expertise in this area to provide input on product development.

And, as part of efforts to prevent the spread of transmissible spongiform encephalopathy, or mad cow disease, FDA scientists are collaborating with colleagues in other government agencies, academia, and industry to develop and assess technologies able to identify prion contamination of biological products. Such tests could be valuable in ensuring the purity of biotechnological manufacturing processes, as well as for screening blood and tissue.

Jill Wechsler is Pharmaceutical Technology's Washington editor, 7715 Rocton Ave., Chevy Chase, MD 20815, tel. 301.656.4634,


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here